FeedingTrends
Glioblastoma Multiforme Treatment Market Was Held at Us$ 2.6 Bn
7 months ago
2 min read

Glioblastoma Multiforme Treatment Market Was Held at Us$ 2.6 Bn

Global sales of Glioblastoma Multiforme Treatment Market in 2021 was held at US$ 2.6 Bn. With 10.1%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth. Radiation Therapy is expected to be the highest revenue generating segment, accounting for an expected CAGR rate of 10.9% during 2022 – 2032.

Download Free Sample Copy of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7187

Key Takeaways from the Market Study

  • Global Glioblastoma Multiforme Treatment Market is estimated to reach a market size of US$ 2.9 Bn by 2022.

  • The Surgery segment is expected to grow at the highest CAGR rate of over 12% during the forecast period.

  • United states is projected to remain the dominant country with absolute dollar opportunity of US$ 1.8 Bn.

  • The market in Japan is set to experience the highest CAGR of 12.8% during the 2022-2032 forecast period.

Competitive Landscape

The market is fiercely competitive, Key players are increasingly focused to obtain a competitive advantage, key companies in the glioblastoma multiforme treatment market are focused on R&D to produce innovative technological products.

  • In April 2021, Lineage Cell Therapeutics signed an agreement with Immunomic Therapeutics to treat glioblastoma multiforme. Under the agreement terms, Lineage will receive a $2 million upfront payment, followed by $67 million in future commercial milestones.

  • In July 2020, Denovo Biopharma, a California-based biotech company, received the FDA’s approval for its phase 2b clinical trial for an analytical combination therapy against glioblastoma tumor tissue.

  • In May 2019, Merck announced its payment of over US$ 1 Bn to complete the acquisition of Peloton Therapeutics, which aims to prevent stroke in patients with glioblastoma using this drug. This M&A holds significant potential to increase Merck’s pipeline and improve their financial ability.

To gain in-depth insights on Glioblastoma Multiforme Treatment Report, request methodology at

https://www.factmr.com/connectus/sample?flag=RM&rep_id=7187

Market Segments Covered in Glioblastoma Multiforme Treatment Market Analysis

By Treatment:

  • Surgery

  • Radiation Therapy

  • Chemotherapy

  • Targeted Therapy

  • Tumor Treating Field (TTF) Therapy

  • Immunotherapy

By Drug Class:

  • Temozolomide

  • Bevacizumab

  • Carmustine Wafers

  • Other Drug Classes

  • Lomustine

By Application:

  • Hospitals

  • Clinics

  • Ambulatory Surgical Centers

By Region:

  • North America

  • Latin America

  • Europe

  • APAC

  • MEA

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the Glioblastoma Multiforme Treatment Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals extensive growth in Glioblastoma Multiforme Treatment Market across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Get Customization on this Glioblastoma Multiforme Treatment Market Report for Specific Research Solutions at

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7187

About the Healthcare Division at Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E-Mail: sales@factmr.com 

Appreciate the creator